Skip to main content

Laxxon Medical

HardwareNew York, NY, United States (headquartered in New York City with R&D facilities in Jena, Germany)Founded 2017· One of 1708 Hardware companies tracked by AMPulse

Laxxon Medical develops 3D screen printing technology (SPID) for structured tablets enabling controlled drug release.

CEO / Founder
Helmut Kerschbaumer
Team Size
11-50
Stage
Active
Total Funding
$12.5M
Latest Round
Series A
Key Investors
Evonik Venture Capital, Crown Fund, German Accelerator, Bavarian Capital Management, bm-t Beteiligungsmanagement Thuringen

Technology & Products

Key Products

SPID Technology Platform, 3D Screen Printed Tablets, Contract development services

Technological Advantage

Patented 3D screen printing faster than traditional 3D printing; enables combination drugs in single tablet

Differentiation

Value Proposition

SPID technology enables mass production of structured tablets with multiple active ingredients and controlled release profiles.

How They Differentiate

Industrial-scale throughput vs. competitors single-unit production; screen printing vs. extrusion

Market & Competition

Target Customers

Pharmaceutical companies, contract manufacturers, drug delivery researchers

Industry Verticals

Pharmaceuticals, Drug Delivery, Contract Manufacturing

Competitors

Aprecia (Drug Delivery), Cyclenium Pharma, Triastek

Growth & Milestones

Growth Metrics

Planning NASDAQ IPO; Multiple drug candidates in development pipeline; Strategic partnership with Evonik for manufacturing

Major Milestones

2017: Founded in Switzerland; 2021: Relocated HQ to US for planned NASDAQ IPO; 2022-03: Strategic investment and partnership with Evonik Venture Capital; 2024-05: Presented LXM.2 GLP-1 agonist at BIO 2024; 2024-06: Presented at BIO San Diego; 2025-12: Published LXM.5 study showing >380% bioavailability vs Sinemet for Parkinson's treatment

Notable Customers

Adare Pharma Solutions (CDMO partner), Hovione (strategic partner), pharmaceutical companies seeking novel drug delivery solutions

https://laxxonmedical.com

Why this company matters

Laxxon Medical occupies a distinct position in pharmaceutical additive manufacturing by applying screen printing—not extrusion or powder bed fusion—to produce structured oral dosage forms. Its SPID technology platform is designed for industrial-scale throughput, a gap left by earlier 3D printing approaches that remain limited to single-unit batch production.

The core process, 3D screen printing, deposits layers of drug-loaded ink through a patterned mesh to build tablets with precise internal geometries. This enables combination drugs with multiple active ingredients and controlled release profiles in a single tablet, a capability difficult to achieve with conventional tableting or extrusion-based 3D printing.

Laxxon targets pharmaceutical companies and contract manufacturers seeking novel drug delivery solutions. A strategic partnership with Evonik Industries covers manufacturing scale-up, and the company has published clinical data showing its LXM.5 formulation achieved over 380% bioavailability versus a reference Parkinson's treatment. Adare Pharma Solutions is another named partner.

The company holds over 230 patents and patent applications covering sequential drug release in dosage forms. Its primary competitive risk comes from established extrusion-based 3D printing players like Aprecia and Triastek, which target similar controlled-release applications but at lower throughput. Laxxon's ability to demonstrate commercial-scale production with multiple pharma partners will determine whether screen printing becomes a standard platform for oral drug manufacturing.